Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Specialty Devices
Drug Delivery Devices
Return to: MDBR Home | Specialty Devices | Drug Delivery Devices

Surefire Medical completes patient enrollment in COSY clinical trial

Published 12 December 2013

US-based Surefire Medical has completed enrollment in the Coiling vs. Surefire infusion system in Y90 (COSY) clinical trial.

This randomized prospective study investigates the feasibility and benefits of performing Selective Internal Radiation Therapy (SIRT), or radioembolization, without the need to place permanent coils.

SIRT is a form of radiation therapy generally used for selected patients with hepatic cell carcinoma or liver metastasis. In the study, half of the patients will have permanent embolic coils placed while the other half will undergo treatment with the Surefire Infusion System without coiling.

The study's primary endpoint is fluoroscopy time. Secondary endpoints are procedure time, radiation dose and contrast dose.

Surefire Medical's scientific advisory board chairman and chief scientific officer Dr Aravind Arepally noted clinical studies show that SIRT can increase the overall survival without adversely affecting the patient's quality of life.

"The goal of this study is to see if this complex, cumbersome workflow can be significantly improved by reducing procedure time and if radiation exposure to both the physician and patient can also be reduced," Arepally added.

Thirty patients have been enrolled at Mount Sinai Hospital in NYC.

Surefire Medical's novel anti-reflux infusion system is a first-in-class medical device designed to maximize direct-to-tumor delivery of cancer-fighting agents and eliminate reflux.

In SIRT treatment and in chemoembolization with Drug Eluting Beads, the unique tip dynamically expands to the vessel walls in reverse flow, potentially reducing damage to healthy tissue while maximizing the dose delivered directly to the target.



Source: Company Press Release